Rupal Tripathi
Overview
Explore the profile of Rupal Tripathi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gupta G, Gupta R, Pasricha S, Sharma A, Durga G, Kamboj M, et al.
Indian J Pathol Microbiol
. 2022 Oct;
65(4):832-838.
PMID: 36308189
Introduction: Urothelial carcinoma poses a significant cause of morbidity and mortality. The recent classification of Tumors of Urinary System by World Health Organization fourth edition) has elucidated its molecular subtypes...
12.
Agrawal C, Goyal P, Agarwal A, Tripathi R, Dodagoudar C, Baghmar S, et al.
Sci Rep
. 2021 Aug;
11(1):16236.
PMID: 34376758
The combination of cyclin dependent kinase 4/6 inhibitors with endocrine therapy is the standard therapy in hormone receptor positive HER-2 negative metastatic breast cancer (HR+/HER2- MBC). Several randomized trials have...
13.
Mehta A, Bansal D, Tripathi R, Jajodia A
J Pathol Transl Med
. 2021 Jun;
55(5):307-316.
PMID: 34147056
Background: SMARCA4/BRG1 protein-deficient lung adenocarcinomas and thoracic sarcoma are recently described entities that lack distinctive histological features, transcription termination factor 1 (TTF1) reactivity, and actionable driver mutations. The current diagnostic...
14.
Tripathi R, Nathany S, Mehta A, Batra U, Mattoo S, Sharma M
Clin Exp Med
. 2021 Mar;
21(3):439-445.
PMID: 33709341
Activating mutations in the KRAS gene (Kirsten rat sarcoma 2 viral oncogene homolog gene) are commonly seen across the various solid organ and hematolymphoid neoplasms. With the likelihood of the...
15.
Gimenez N, Tripathi R, Giro A, Rosich L, Lopez-Guerra M, Lopez-Oreja I, et al.
Sci Rep
. 2020 Dec;
10(1):22153.
PMID: 33335123
Chronic lymphocytic leukemia (CLL) is a B lymphoid malignancy highly dependent on the microenvironment. Despite new targeted therapies such as ibrutinib and venetoclax, disease progression and relapse remain an issue....
16.
Bajaj R, Tripathi R, Sridhar T, Korlimarla A, Choudhury K, Suryavanshi M, et al.
PLoS One
. 2020 Nov;
15(11):e0242190.
PMID: 33175907
Background: The study assessed the epigenetic regulation and the role of microRNA (miR) expression in locally advanced triple negative breast cancers (TNBC) and comparison with the clinico-pathological variables and survival....
17.
Mehta A, Verma A, Gupta G, Tripathi R, Sharma A
Indian J Hematol Blood Transfus
. 2020 Oct;
36(4):627-634.
PMID: 33100703
Double hit lymphomas (DHL) and double expresser lymphomas (DEL) are subsets of diffuse large B cell lymphomas (DLBCL) which are being increasingly recognised as cause of treatment failure. This emphasizes...
18.
Chandra Doval D, Tripathi R, Gupta M, Mehta A, Goyal P, Agrawal C, et al.
Breast J
. 2020 Oct;
26(11):2255-2256.
PMID: 33007790
No abstract available.
19.
Verma P, Jain S, Kapoor G, Tripathi R, Sharma P, Chandra Doval D
J Pediatr Hematol Oncol
. 2020 Sep;
43(4):e466-e471.
PMID: 32925402
Background: Cisplatin and doxorubicin are integral components of chemotherapy regimens in the treatment of osteosarcoma. Choice of third agent high-dose methotrexate (HDMTX) or an alkylating agent such as ifosfamide is...
20.
Nathany S, Tripathi R, Mehta A
J Clin Pathol
. 2020 Sep;
74(1):1-4.
PMID: 32907914
The is a general transcription factor and its mutations have been reported to be recurrent in thymic epithelial tumours and are rare in other malignancies. Apart from thymic epithelial tumours,...